Skip to main content

GPC Biotech Licenses IP from Ariad

NEW YORK, Feb. 4 - GPC Biotech of Martinsried, Germanyhas non-exclusively licensed patents from Ariad pharmaceuticals in the area of cell-signaling regulation technology, the company said today.


This additional IP allows the company to add this technology to its LeadCode drug discovery platform, a modified yeast two-hybrid proteomics methodology that screens for interactions between a small molecule and the full complement of human proteins.


This new IP licensing agreement follows on the heels of GPC's collaboration with Eli Lilly Jan. 31 to use LeadCode for mechanism of action studies on a class of metabolic disease lead compounds.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.